Skip to content

The efficacy of mindfulness‐based cognitive therapy to improve depression symptoms and quality of life in individuals with memory difficulties and caregivers: A short report

Lana J. Ozen, Sacha Dubois, Megan M. English, Carrie Gibbons, Hillary Maxwell, Jessica Lowey, Erica Sawula, Michel Bédard

Alzheimer’s & Dementia: Translational Research & Clinical Interventions December 27, 2022 DOI: 10.1002/trc2.12252 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Randomized controlled trial Peer reviewed
Population Older adults with memory difficulties and their caregivers
Topics Depression Meditation
Keywords Caregivers Cognitive impairment Cognitive therapy Memory
Key findings MBCT did not significantly affect depression, anxiety, or mindfulness outcomes, but improvements in non-judgmental awareness correlated with reduced depression symptoms in both groups.

Abstract

Abstract Introduction Depression symptoms are common for older adults with memory difficulties and their caregivers. Mindfulness‐based cognitive therapy (MBCT) reduces the risk of relapse in recurrent depression and improves depression symptoms. We explored recruitment and retention success and preliminary effect sizes of MBCT on depression and anxiety symptoms, as well as mindfulness facets, in individuals with memory difficulties and their caregivers.

Methods: A difficulty with memory group (DG) and caregiver group (CG) were randomized into either the MBCT intervention or waitlist control. After serving as controls, participants received the intervention. Mean pre–post changes by group were compared and effect sizes computed. Correlations between mindfulness facets and depression symptoms are also presented.

Results: Only 47% of the initial participants completed the study. The intervention did not have an effect on the outcome variables examined. However, improvements in non‐judgmental scores were associated with reductions in the number of depression symptoms reported by DG participants (r = –0.90, 95% confidence interval [CI]: –0.98, –0.52) and CG participants (r = –0.76, 95% CI: –0.95, –0.19). Furthermore, improvements in awareness scores (r = –0.69, 95% CI: –0.93, –0.05) and level of burden (r = 0.87, 95% CI: 0.49, 0.97) also significantly correlated with reduced depression symptoms in the CG group.

Conclusions: By determining preliminary MBCT effect sizes in individuals with memory difficulties and their caregivers, research with larger, controlled samples is now justified to determine the true effects of MBCT in these populations.

Comparable studies

Other randomized controlled trials on depression, most cited first.

Study Year Design Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant) 2006 Randomized, placebo-controlled, double-blind crossover study n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients 2000 Randomized controlled trial n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety 2016 Randomized controlled trial n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression 2016 Double-blind, placebo-controlled, crossover trial n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients 2004 Randomized controlled trial n = 73

Citations in the library

Explore topics